A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy

Phase 3 CoMpass is SPA-agreed, fully enrolled (108 pts), sham-controlled with time-to-tumor-progression endpoint. Positive Phase 2 end-of-study data and mechanistically strong VDC with FDA Fast Track/Orphan support success odds above base rate. However, small trial size, sham control durability, and 15-month endpoint variability add risk. Topline not until 2H27, well past this market's window—resolution timing risk is significant.reasoning tilts moderately positive.:

Phase 3 RCT, masked, sham-controlled for bel-sar vs control in IL/small CM. Primary endpoint: time-to-tumor progression (65 weeks). Active not recruiting, enrollment complete. Standard pivotal design with adequate power expected; no design/operational red flags in fields.

Phase 2 data demonstrated an 80% tumor control rate in Phase 3-eligible patients, with the tumor growth rate dropping from 0.351 mm/yr pre-treatment to 0.011 mm/yr post-treatment (p<0.0001). The Phase 3 CoMpass trial enriches for patients with documented tumor growth prior to enrollment and compares bel-sar to a sham control, making a positive time-to-progression result highly probable.

Phase 3 sham-controlled trial of novel light-activated therapy for small choroidal melanoma. Prior Phase 2 data encouraging but small; risk of sham arm performing better than expected and masking challenges. Time-to-progression endpoint is objective but progression determination may be influenced. Typical Phase 3 oncology success ~40-50%, so intrinsic odds slightly below 50%.

Bel-sar (AU-011) showed strong Phase 2 signals in indeterminate lesions and small choroidal melanoma, with high rates of tumor shrinkage and low progression. The time-to-progression endpoint against sham control is well-suited to demonstrate benefit given expected progression in untreated arm. Phase 3 risk remains, but mechanism and prior data support a positive outcome.

Bel-sar targets indeterminate lesions/small melanoma with a novel mechanism. Phase 2 data showed strong efficacy in preventing progression. The primary endpoint (time to progression) is objective. Active status suggests operational stability. Historical success in this niche supports a positive outcome, though Phase 3 risks remain.

Phase 3 ocular melanoma trial with time-to-progression endpoint at 65 weeks. Bel-sar is a novel virus-like drug+device combo requiring precise suprachoroidal delivery. Prior Phase 2 showed activity but small sample (n=~20). Sham control is appropriate. Primary completion 454 days out means data immature. Current status 'Active Not Recruiting' suggests enrollment complete but no interim reads disclosed. Tumor progression endpoint in indeterminate lesions/small CM is challenging—natural history variable, sham arm may do well. No prior Phase 3 validation for this mechanism in this indication....

Phase 3 ocular melanoma trial with time-to-progression endpoint at 65 weeks. Bel-sar is a novel viral-like drug-device combo with promising Phase 2 data but limited long-term follow-up. Sham control in vision-threatening tumors creates ethical/operational execution risk and potential unmasking. Small tumor population and indeterminate lesion heterogeneity may dilute effect. 460 days to completion adds disclosure risk. Prior data supportive but not definitive; mechanism is innovative but unproven at scale.

Bel-sar Phase 3 with rigorous sham-controlled design in small choroidal melanoma/indeterminate lesions. Encouraging Phase 2 tumor control data and FDA Breakthrough Designation support optimism, but Phase 3 transition risk, novel viral-nanoparticle laser-activated mechanism, and small Phase 2 cohorts (n<50) create meaningful uncertainty. Sham control may progress slower than historical controls, making bar higher. Active not recruiting status suggests clean enrollment. Overall slightly below coin-flip given execution risks in rare ocular oncology.